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effects, efficiently improve the human body health with very low toxicity. This review article elaborates 
the current challenges and prospective of   surface modified drug carrier systems for delivery of protein 
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The concept of a drug carrier with targeted specificity has 
captivated scientists for many years, and successful efforts have 
been made in the last decade to achieve this goal [1]. The 
ultimate form of targeted drug delivery system should be a 
realisation of Paul Ehrlich's "magic bullet concept," which 
documents drug delivery to a preselected targeted cell type 
exclusively [2]. 
 
Liposomes have recently gained prominence among all targeted 
drug delivery systems due to their biological inertness, lack of 
antigenic, pyrogenic, or allergic reactions, and increased 
stability. Liposomes are colloidal or microparticulate carriers 
that develop spontaneously when such lipids are hydrated in 
 
_______________________________________________________________________________________________ 





aqueous media [3]. Liposomes are made of biocompatible and 
biodegradable materials and are made up of aqueous volume 
trapped by one or more bilayers of natural or synthetic lipids. 
Highly lipophilic drugs with a partition coefficient greater than 
5 are almost entirely entrapped in the lipid bilayer of liposomes. 
 
Antineoplastic agents used to treat lung cancer, solid tumors, 
testicular cancer, breast cancer, many forms of leukaemia, 
lymphoma, and other cancers have been linked to a variety of 
serious side effects, including bone marrow depression, which 
induces granulocytopenia, agranulocytosis, throbocytopenia, 
and aplastic anaemia, lymphocytopenia, and suppression of 
lymphocyte function.  
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Chemotherapy for cancer is often associated with harmful side 
effects. Cancer could be treated without side effects if an 
anticancer drug could only deliver the right dose at the right time 
to the right place. Since liposomes are basically non-toxic and 
biodegradable, their size, materials, and modifications with 
different molecules are easily regulated, and they can deliver 
large amounts of either hydrophilic or hydrophobic agents, 
liposomal formulation is thought to be useful for such delivery 
method. 
 
Liposome delivery to the right place is always a work in 
progress. Active and passive targeting are also taken into 
consideration for this reason. Conventional liposomes, on the 
other hand, are often stuck by the reticuloendothelial system 
[RES] in organs like the liver and spleen before reaching their 
intended destination. On the other hand, since the vasculature in 
tumor tissues is leaky enough to extravasate liposomes and 
circulating liposomes can accumulate passively in tumor tissues, 
passive targeting, especially targeting to tumor tissues, could be 
achieved by reducing RES trapping. Liposomes containing lipid 
derivatives of PEG or saturated phospholipids such as DSPC 
with cholesterol have rendered targeted liposomal therapy more 
feasible by decreasing RES uptake and thereby prolonging 
circulation period [4]. 
 
PEG is particularly useful due to its ease of preparation, low 
cost, molecular weight controllability, and ability to bind to 
lipids or proteins, including antibodies, using a variety of 
methods. PEG inhibits serum protein binding, i.e. opsonins, 
which mark the liposome for macrophage clearance. Antibodies 
should be bound to the distal end of PEG chains that are already 
attached to the liposome membrane, according to our hypothesis. 
In order to prepare long circulating [RES avoiding] liposomes, 
we have chosen several functionalized PEG derivatives such as 
DPPE-PEG-Mal and DSPE-PEG. 
 
The most common approach for actively targeting liposomes to 
tumor cells is to bind ligands to the liposomal surface, allowing 
for a precise interaction with the tumor cells. Antibodies or 
antibody fragments, vitamins, glycoproteins, peptides [RGD-
sequences], and oligonucleotide aptamers have all been used as 
ligands for this function. Immunoliposomes, which use an 
antibody or antibody fragment as a targeting ligand and a lipid 
vesicle as a carrier for both hydrophilic and hydrophobic drugs, 
are a fascinating prospect in cancer therapy among the various 
active targeting approaches. The transport phase, in which 
immunoliposomes migrate from the site of administration [often 
i.v. administration] to the target cells, and the effector phase, 
which involves precise binding of immunoliposomes to target 
cells and subsequent delivery of entrapped drugs, are the two 
stages of targeted drug delivery with immunoliposomes. 
 
Immunoliposomes for tumor treatment must meet a set of 
criteria aimed at maximising the targeting effect of 
immunoliposomes provided systemically in the bloodstream. 
The antigen binding site of the liposome-conjugated antibody 
must be accessible in order for the antibody to associate with 
antigen on the surface of target cells without being disrupted. In 
contrast to the rate of extravasation in the tumor, 
immunoliposome blood clearance must be reduced. The 
immunooliposome must be able to effectively load and maintain 
a particular anticancer drug. Finally, drug and antibody 
integration must be safe enough to allow liposomal entry into 
tumor tissue while neither of these agents is lost. 
 
In the proposed work, an attempt is made to establish long 
circulating [RES avoiding] immunoliposomes for site specific 
delivery of selected anticancer drugs by adding functionalized 
PEG derivatives over the liposome membrane and attaching a 
suitable monoclonal antibody to the distal end of the PEG chain.  
Compared to traditional liposomes, long circulating 
immunoliposomes have the following advantages. 
1. Decreased RES uptake and prolonged circulation time 
2. Selective active targeting to tumor tissues 
3. Increased efficacy and therapeutic index 
4. Reduction in toxicity of encapsulated agent  
 
The creation of hybridoma technology, which enables a large 
quantity of monoclonal antibodies to a wide variety of cell 
determinants to be generated, has aided the use of an antibody 
molecule as a homing device. The monoclonal antibody 21B2 or 
MN-14, which is specific for the human carcinoembryonic 
antigen [CEA], was chosen for this study to see whether 
immunoliposomes injected intravenously would extravasate into 
solid tumor tissue and bind to tumor cells. We've also chosen 
CEA positive human gastric cancer strain MKN-45, as well as 
other CEA positive human solid tumor strains [Endocervical 
adenocarcinoma, epithelial ovarian cancer, and etc]. Again, 
instead of using the entire antibody, the current study is 
attempting to use the Fab' fragment, which reduces the 
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immunogenic effect of the Fc part and improves RES clearance 
through precise recognition by phagocytic cells carrying Fc 
receptors. Via specific thiol groups in the hinge region, Fab' 
fragments also allow for better conjugation to liposomes 
containing DPPE-PEG-Mal. 
 
SURFACE MODIFICATION OF NANOFORMULATIONS 
Surface alteration of nanoparticles changes their surface 
properties and improves the delivery system's performance in 
biological environments. Covalent bond formation between the 
functional groups on the surface and the ligands is typically used 
to conjugate the nanocarrier's surface with a particular ligand [5].  
 
Surface alteration techniques include electrostatic adsorption 
and surface coating. The existence of various functional groups 
on the surface of albumin nanoparticles, such as carboxylic and 
amino groups, offers various possibilities for surface 
modification of dependent delivery systems. The following are 
ligands that are used for a variety of purposes ranging from 




Surfactants are used in formulation to adjust the 
pharmacokinetic parameters. Modifications with Polysorbate 
80, for example, effectively decreased doxorubicin's multiple 




PEGylation of delivery systems is done to reduce their 
immunogenicity and extend their circulation half-life, thus 
increasing nanoparticles' passive tumor targeting capability [8]. 
 
Cationic polymers 
Cationic polymers are mostly used to delay the release of drugs. 
The only way to secure nanoparticles from enzymatic 
degradation is to coat them with biocompatible materials, which 
eliminates the use of dangerous crosslinkers for nanoparticle 
stabilisation, such as glutaraldehyde crosslinking, which is used 
to stabilise albumin and gelatin nanoparticles prepared through 
desolvation or coacervation. Surface coating of anionic albumin 
nanoparticles with cationic polymers such as polyethylenimine 
[PEI] can regulate the rate of drug release and is dependent on 
the concentrations of PEI used for coating [9]. 
Thermosensitive polymers 
Shen et al. developed new thermal targeting drug carriers by 
carbodiimide [EDC] coupling the thermo-responsive poly [N-
isopropylacrylamide-coacrylamide]-block-polyallylamine 
[PNIPAM-AAm-b-PAA] to the carboxylic group on the surface 
of albumin nanospheres, and successful targeting was observed 
with these nanoparticles [10]. 
 
Folic acid 
Folic acid receptors are one of the many receptors that are 
overexpressed in cancer cells. Folic acid is a vitamin with a low 
molecular weight. Folic acid has many advantages as a targeting 
agent, including its stability, low cost, non-immunogenic nature, 
compatibility with organic solvents used during processing, and 
the fact that it is the primary substrate for folate receptors; it 
binds to folate receptors at cell surfaces with high affinity and is 
internalised through receptor mediated endocytosis [11]. The 
carboxylic group of folic acid was conjugated to the amino 
groups on the surface of albumin nanoparticles using the 
carbodiimide [EDC] coupling technique [12]. 
 
Monoclonal antibodies [mAbs] 
mAbs are an interesting group of ligands that have emerged for 
tumor targeting. Many cancers, including breast, ovarian [13], 
colorectal, non-small cell lung, head, neck, and prostate cancers, 
as well as glioma, have surface overexpression of the epidermal 
growth factor receptor [EGFR]. EGFR-2 [HER2] is used as a 
tumor targeting marker in the treatment of patients with 
metastatic breast cancer [14]. Trastuzumab [Herceptin®], a 
humanised anti-HER2 specific antibody, was used to modify the 
surface of the nanoparticles by forming an avidin–biotin 
complex between the biotin-binding protein [NeutrAvidin] 
attached to the nanoparticles and the biotinylated antibody for 
Human serum albumin [HSA] nanoparticle. In HER2-
overexpressing cells [cell lines BT474, MCF7, and SK-BR-3], 
Wartlick et al. conjugated HSA nanoparticles with trastuzumab 
and evaluated them in HER2-overexpressing cells [cell lines 
BT474, MCF7, and SK-BR-3] and found that successful 
internalisation of the nanoparticles through receptor-mediated 
endocytosis is time and dose dependent [15]. 
 
Peptides and proteins 
In the literature, Expression of high levels of αvβ3 integrin [a 
membrane receptor for extracellular matrix ligands such as 
vitronectin and fibronectin] have been found in cancer cells from 
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different entities [16]. The cyclic arginine–glycine–aspartic acid 
[RGD] peptide ligand has a high binding affinity for the αvβ3 
integrin [17]. Dubey et al. prepared RGD peptide-anchored 
sterically stabilised BSA nanospheres [RGD-SN] containing 5-
fluorouracil for targeting tumor vasculature, and found that 
RGD-SN is significantly more efficient than free fluorouracil in 
preventing lung metastasis, angiogenesis, and effective tumor 
regression [18]. 
 
Preclinical and Clinical Investigations of Nanoparticles  
Albumin-paclitaxel nanoparticles made with novel nab 
technology have a diameter of 130 nm and were approved for 
the treatment of metastatic breast cancer in 2005. In a phase I 
review, the toxicity profile, pharmacokinetics, and mean 
therapeutic dose [MTD] of nab-paclitaxel were investigated 
[19]. Nineteen patients with advanced solid tumors obtained 
doses ranging from 135 to 375 mg/m2 as an infusion without any 
premedication. There was just minor hematologic toxicity. At 
the maximum dose tested [375 mg/m2], two patients developed 
grade 3 superficial keratopathy. 300 mg/m2 was determined to 
be the MTD. Ibrahim et al. came to the conclusion that nab-
paclitaxel can be provided quickly and safely without the need 
for premedication. 63 women with metastatic breast cancer 
received 300 mg/m2 nab-paclitaxel by intravenous infusion 
without premedication in a multicenter phase II trial [20]. 
Despite the lack of premedication, no serious hypersensitivity 
reactions were identified in the phase II analysis. Routine 
ophthalmological tests showed no serious ocular events like 
superficial keratopathy, indicating that this toxicity occurred by 
chance in the phase I sample or only occurs at doses higher than 
the MTD. 210 Chinese patients with metastatic breast cancer 
were enrolled in an open-label multicenter phase III trial. In 
contrast to solvent-based paclitaxel, preliminary findings 
indicated that nab-paclitaxel offers higher response rates and a 
longer time to tumor progression without increased toxicity [21]. 
 
In a variety of human tumor xenograft models, nab-paclitaxel 
has outperformed paclitaxel in terms of antitumor efficacy. At 
the MTDs, however, mice treated with nab-paclitaxel showed a 
substantial improvement in antitumor response. Data on nab-
antitumor paclitaxel's response and tumor uptake were 
comparable to albumin-binding prodrugs like DOXO-EMCH. 
The change of the MTD of nab-paclitaxel and DOXO-EMCH 
over the respective free drug in mice resulted in an average 
increase in drug tumor accumulation of 3 to 6 fold at an equitoxic 
comparison. At an equitoxic contrast, there is a 3 to 6 fold rise 
in drug tumor accumulation. The pathophysiology of tumor 
tissue is defined by angiogenesis, hypervasculature, and 
impaired lymphatic drainage, and it mediates the enhanced 
absorption of albumin-based drug delivery systems in solid 
tumors. Transcytosis induced by albumin binding to a cell's 60-
kDa glycoprotein receptor, as well as albumin binding to 
SPARC [secreted protein acid and rich in cysteine], increases 
nab-paclitaxel accumulation in tumor cells [22]. Abraxane was 
tested for adjuvant, neoadjuvant, and first-line treatment of 
breast cancer, as well as other indications such as non-small cell 
lung cancer, ovarian cancer, and pancreas cancer, after receiving 
FDA approval. Other nab-technology-based products in clinical 
trials include those containing docetaxel, rapamycin, and other 
drugs. 
 
Transferrin protein was coupled to various nanoparticles to 
achieve targeted delivery to cancerous cells. When doxorubicin-
loaded apotransferrin nanoparticles were administered 
intraperitoneally, they transmitted the drug more effectively 
against cell-mediated ascetic liver cancer than free doxorubicin. 
Hepatocytes take up transferrin-bound iron through receptor-
mediated endocytosis into a low-density vesicle compartment, 
which is followed by iron release and transferrin recycling. 
However, it has been stated that transferrin receptor-1, 
transmembrane protein divalent metal transporter 1 [DMT1], 
and divalent metal transporter ZIP14 are all involved in 
transferrin-mediated iron transport. 
 
Gelatin-based nanoparticles were used to deliver pDNA 
encoding VEGF receptor-1 in the body [23][24]. Gelatin [Gel], 
thiolated gelatin [SHGel], and polyethylene glycol-modified 
gelatin [PEG-Gel], as well as polyethylene glycol-modified 
thiolated gelatin, were used to encapsulate pDNA [PEG-SHGel]. 
Several anticancer genes can be delivered by a variety of gelatin-
based delivery systems, according to in vivo studies. Following 
intravenous administration of and PEG-SHGel nanoparticles, 
approximately 13-15% of the recovered dose accumulated in the 
tumor for up to 12 hours, according to a gelatin-based delivery 
method. Overall, PEG-Gel nanoparticles [25]can provide a safe 
and effective method for delivering therapeutic plasmid to solid 
tumors. In addition, in vivo studies showed that cationic gelatin 
microspheres containing NK4 pDNA inhibited angiogenesis in 
Lewis lung carcinoma tumors and suppressed disseminated 
pancreatic cancer cells. 
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Epidermal Growth Factor Receptor Targeting in Cancer 
The epidermal growth factor receptors [EGFR]/Her1/ErbB1 are 
cell-surface receptors that belong to the ErbB family of tyrosine 
kinases. Because of their abnormal expression in many epithelial 
tumors and their effect on growth and survival in malignant 
states, they have gained a lot of attention for molecular targeting 
of cancer therapeutics [26]. Many therapeutic agents have been 
developed as a result of advances in genetic engineering and 
understanding of the EGFR signaling pathways in cancer, 
including monoclonal antibodies [mAbs], small molecule 
tyrosine kinase inhibitors [TKIs], antisense oligonucleotides, 
antibody dependent immuno-conjugates, and other agents such 
as FR-18, peptides, affibodies, nanobodies, and others [27] [28]. 
 
By blocking the ligand-binding region, mAbs bind to the 
extracellular domain of EGFR and compete with endogenous 
ligands to inhibit ligand-induced EGFR tyrosine kinase 
activation[29] [30]. The two most advanced mAbs that target the 
extracellular domain of the EGFR are cetuximab and 
panitumumab. Cetuximab [Erbitux] is a chimeric [mouse/ 
human] monoclonal antibody for intravenous infusion that was 
approved by the United States Food and Drug Administration 
[USFDA] in February 2004 for the treatment of metastatic 
colorectal and head/neck cancer [31]. Panitumumab [Vectibix], 
on the other hand, is a completely human mAb specific to EGFR 
that was approved by the USFDA in September 2006 for 
metastatic colorectal cancer. Panitumumab was the first 
monoclonal antibody [mAb] to show that KRAS [Kristen RAS] 
can be used as a predictive biomarker, and it was approved by 
the European Medicines Agency in 2007 and Health Canada in 
2008 for the treatment of refractory EGFR-expressing metastatic 
colorectal cancer in patients with wild-type KRAS. In July 2009, 
the US Food and Drug Administration approved Erbitux for the 
treatment of KRAS wild form [non-mutated] colon cancer. 
 
CONCLUSION  
The research on receptor-mediated nanocarriers is currently very 
active, progressing from studies on non-therapeutic targets to 
studies on therapeutic targets. More research on these systems 
against multiple receptors, as well as hybrid therapies with 
receptor-mediated nanocarriers, have recently been released. 
However, we still have a long way to go, especially in terms of 
understanding receptors, which is crucial for receptor-mediated 
delivery. The primary advantage of receptor-mediated 
nanocarriers over passive nanocarriers may be their ability to 
accumulate within tumors for longer periods of time due to their 
binding to and/or absorption by cancer cells, preventing rapid 
redistribution into the systemic circulation. Ongoing research on 
different forms of drug delivery systems based on receptor 
mediation are discussed, as well as the potential and challenges, 
and a future study pattern is introduced. 
 
FINANCIAL ASSISTANCE  
Nil 
 
CONFLICT OF INTEREST  
The authors declare no conflict of interest. 
 
AUTHOR CONTRIBUTION 
Shiroya Milankumar Nathabhai and Fenil Vanpariya designed 
the work and made necessary corrections and revisions in the 
manuscript. Miteshkumar Malaviya collected the content and 
performed the literature review and also contributed to drafting 
the manuscript. All the authors framed the final manuscript. 
 
REFERENCES  
[1] Saul JM, Annapragada A, Natarajan J V., Bellamkonda R 
V. Controlled targeting of liposomal doxorubicin via the 
folate receptor in vitro. J. Control. Release, 92, 49–67 
(2003). 
[2] Singh R, Lillard JW. Nanoparticle-based targeted drug 
delivery. Exp. Mol. Pathol., 86, 215–23 (2009). 
[3] Sharma A, Sharma US. Liposomes in drug delivery: 
Progress and limitations. Int. J. Pharm., 154, 123–40 
(1997). 
[4] Oku N. Anticancer therapy using glucuronate modified 
long-circulating liposomes. Adv. Drug Deliv. Rev., 40, 63–
73 (1999). 
[5] Oake A, Bhatt P, Pathak Y V. Understanding Surface 
Characteristics of Nanoparticles. Surface Modification of 
Nanoparticles for Targeted Drug Delivery. Springer 
International Publishing, pp.1–17 (2019). 
[6] Pereverzeva E, Treschalin I, Bodyagin D, Maksimenko O, 
Langer K, Dreis S, Asmussen B, Kreuter J, Gelperina S. 
Influence of the formulation on the tolerance profile of 
nanoparticle-bound doxorubicin in healthy rats: Focus on 
cardio- and testicular toxicity. Int. J. Pharm., 337, 346–56 
(2007). 
[7] Patel P, Hanini A, Shah A, Patel D, Patel S, Bhatt P, Pathak 
Y V. Surface Modification of Nanoparticles for Targeted 
Drug Delivery. Surface Modification of Nanoparticles for 
Journal of Applied Pharmaceutical Research 9 (1); 2021: 01 – 07   Malviya et. al  
 
 
  Journal of Applied Pharmaceutical Research (JOAPR)| January – March 2021 | Volume 9 Issue 1 |   6 
Targeted Drug Delivery. Springer International Publishing, 
pp.19–31 (2019). 
[8] Brannon-Peppas L, Blanchette JO. Nanoparticle and 
targeted systems for cancer therapy. Adv. Drug Deliv. Rev., 
56, 1649–59 (2004). 
[9] Singh HD, Wang G, Uludaǧ H, Unsworth LD. Poly-L-
lysine-coated albumin nanoparticles: Stability, mechanism 
for increasing in vitro enzymatic resilience, and siRNA 
release characteristics. Acta Biomater., 6, 4277–84 (2010). 
[10] Shen ZY, Ma GH, Dobashi T, Maki Y, Su ZG. Preparation 
and characterization of thermo-responsive albumin 
nanospheres. Int. J. Pharm., 346, 133–42 (2008). 
[11] Oyewumi MO, Mumper RJ. Influence of formulation 
parameters on gadolinium entrapment and tumor cell uptake 
using folate-coated nanoparticles. Int. J. Pharm., 251, 85–
97 (2003). 
[12] Shen Z, Li Y, Kohama K, Oneill B, Bi J. Improved drug 
targeting of cancer cells by utilizing actively targetable folic 
acid-conjugated albumin nanospheres. Pharmacol. Res., 63, 
51–8 (2011). 
[13] Bhatt P, Lalani R, Mashru R, Misra A.  Abstract 2065: Anti-
FSHR antibody Fab’ fragment conjugated 
immunoliposomes loaded with cyclodextrin-paclitaxel 
complex for improved in vitro efficacy on ovarian cancer 
cells , Cancer Research, July, 2016, American Association 
for Cancer Research (AACR), pp.2065–2065. 
[14] Bhatt P, Vhora I, Patil S, Amrutiya J, Bhattacharya C, Misra 
A, Mashru R. Role of antibodies in diagnosis and treatment 
of ovarian cancer: Basic approach and clinical status. J. 
Control. Release, 226, 148–67 (2016). 
[15] Wartlick H, Michaelis K, Balthasar S, Strebhardt K, Kreuter 
J, Langer K. Highly specific HER2-mediated cellular 
uptake of antibody-modified nanoparticles in tumor cells. J. 
Drug Target., 12, 461–71 (2004). 
[16] Bello L, Zhang J, Nikas DC, Strasser JF, Villani RM, 
Cheresh DA, Carroll RS, Black PML. αvβ3 and αvβ5 
Integrin expression in meningiomas. Neurosurgery, 47, 
1185–95 (2000). 
[17] Lalani RA, Bhatt P, Rathi M, Misra A. Abstract 2063: 
Improved sensitivity and in vitro efficacy of RGD grafted 
PEGylated gemcitabine liposomes in RRM1 siRNA 
pretreated cancer cells, Cancer Research, July, 2016, 
American Association for Cancer Research (AACR), 
pp.2063–2063. 
[18] Dubey PK, Singodia D, Verma RK, Vyas SP. RGD 
modified albumin nanospheres for tumor vasculature 
targeting. J. Pharm. Pharmacol., 63, 33–40 (2011). 
[19] Malaviya M, Shiroya M. Systemic gene delivery using lipid 
envelope systems and its potential in overcoming 
challenges. Int. J. Pharm. Drug Anal., 9, 46–55 (2021). 
[20] Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao 
SC, Nair MK, Bhar P, Desai N, Hortobagyi GN. Multicenter 
phase II Trial of ABI-007, an albumin-bound paclitaxel, in 
women with metastatic breast cancer. J. Clin. Oncol., 23, 
6019–26 (2005). 
[21] Guan Z, Feng F, Li QL, Jiang Z, Shen Z, Yu S, Feng J, 
Huang J, Yao Z, Hawkins MJ. Randomized study 
comparing nab-paclitaxel with solvent-based paclitaxel in 
Chinese patients (pts) with metastatic breast cancer (MBC). 
J. Clin. Oncol., 25, 1038–1038 (2007). 
[22] Porter PL, Sage EH, Lane TF, Funk SE, Gown AM. 
Distribution of SPARC in normal and neoplastic human 
tissue. J. Histochem. Cytochem., 43, 791–800 (1995). 
[23] Streets J, Bhatt P, Bhatia D, Sutariya V. Sunitinib-loaded 
MPEG-PCL micelles for the treatment of age-related 
macular degeneration. Sci. Pharm., 88, 1–12 (2020). 
[24] Narvekar P, Bhatt P, Fnu G, Sutariya V. Axitinib-Loaded 
Poly(Lactic-Co-Glycolic Acid) Nanoparticles for Age-
Related Macular Degeneration: Formulation Development 
and in Vitro Characterization. Assay Drug Dev. Technol., 
17, 167–77 (2019). 
[25] Bhatt P, Narvekar P, Lalani R, Chougule MB, Pathak Y, 
Sutariya V. An in vitro Assessment of Thermo-Reversible 
Gel Formulation Containing Sunitinib Nanoparticles for 
Neovascular Age-Related Macular Degeneration. AAPS 
PharmSciTech, 20, (2019). 
[26] Zaczek A, Brandt B, Bielawski KP. The diverse signaling 
network of EGFR, HER2, HER3 and HER4 tyrosine kinase 
receptors and the consequences for therapeutic approaches, 
Histol Histopathol, 2005. 
[27] Patel J, Amrutiya J, Bhatt P, Javia A, Jain M, Misra A. 
Targeted delivery of monoclonal antibody conjugated 
docetaxel loaded PLGA nanoparticles into EGFR 
overexpressed lung tumor cells. J. Microencapsul., 35, 204–
17 (2018). 
[28] Yewale C, Baradia D, Patil S, Bhatt P, Amrutiya J, Gandhi 
R, Kore G, Misra A. Docetaxel loaded 
immunonanoparticles delivery in EGFR overexpressed 
Journal of Applied Pharmaceutical Research 9 (1); 2021: 01 – 07   Malviya et. al  
 
 
  Journal of Applied Pharmaceutical Research (JOAPR)| January – March 2021 | Volume 9 Issue 1 |   7 
breast carcinoma cells. J. Drug Deliv. Sci. Technol., 45, 
334–45 (2018). 
[29] Bier H, Hoffmann T, Haas I, Van Lierop A. Anti-(epidermal 
growth factor) receptor monoclonal antibodies for the 
induction of antibody-dependent cell-mediated cytotoxicity 
against squamous cell carcinoma lines of the head and neck. 







































[30] Normanno N, Pergameno M, Iannaccone A, De Luca A. 
Mechanisms of action of EGFR inhibitors. EGFR Inhibitors 
in Cancer Treatment. Future Medicine Ltd., pp.7–17 
(2012). 
[31] Wong SF. Cetuximab: An epidermal growth factor receptor 
monoclonal antibody for the treatment of colorectal cancer. 
Clin. Ther., 27, 684–94 (2005). 
 
 
